This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmAthene Presents New Anthrax Data At The 5th Annual PHEMCE Stakeholders Workshop And BARDA Industry Day

ANNAPOLIS, Md., Jan. 13, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that the Company recently presented new data from its anthrax anti-toxin and recombinant Protective Antigen (rPA) anthrax vaccine programs at the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) Stakeholders Workshop and the Biomedical Advanced Research and Development Authority (BARDA) Industry Day, held January 11 – 13, 2011 in Washington, DC.

"BARDA continues to move forward to work closely with industry in the development and procurement of new medical countermeasures," commented Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer of PharmAthene.  "We are delighted to present new data from our biodefense programs, which demonstrate progress towards our shared goal of enhancing biodefense national security initiatives.  As the data illustrate, PharmAthene continues to advance its pipeline and further its leadership position in biodefense."

Valortim® Anthrax Anti-Toxin Findings Reported

In an oral presentation entitled, "Comparison of Functional Activity and Pharmacokinetic Data from Nonclinical Valortim® Efficacy Studies: Implications for the Animal Rule" Dr. James Bourdage, Director of Bioanalytical Assay Development, at PharmAthene presented a biostatistical analysis of pharmacokinetic and toxin neutralization assay results for multiple Valortim ® doses in three separate animal species – the African Green Monkey, New Zealand White Rabbit and Cynomolgus Monkey.

In these studies, animals were exposed to anthrax spores and subsequently treated with various doses of Valortim ® upon detection of antigenemia (evidence of bacterial infection in the bloodstream) and/or significant increases in body temperature (in the case of New Zealand White rabbits).  Pharmacokinetic (PK) analysis of serum samples was conducted utilizing a capture ELISA assay and a toxin neutralization assay (TNA).

Comparisons of the pharmacokinetic and toxin neutralization results for multiple Valortim ® doses across the three separate species indicated that the TNA/PK ratios were relatively consistent within individual animals across various time points ranging from five minutes to five days for doses ranging from 2.5 to 40 mg/kg.  While the absolute ratios differed slightly for some animals, the consistency of these ratios across time, regardless of dose, species, or animal outcome, suggests the suitability of these assays in providing reliable data to support the Food and Drug Administration's use of the 'The Animal Rule' to approve new drugs or biological products when human efficacy studies are not ethical or feasible.

Dr. Bourdage commented, "Despite the presence of potentially interfering substances in animals with active disease, we're very encouraged that two separate assays evaluating Valortim ® concentration and functional activity demonstrated comparable results.  In our opinion, this suggests the utility of these assays in providing data to support use of the Animal Rule for the approval of novel medical countermeasures, and thus represents a potentially important advance in the development of monoclonal antibody-based anthrax anti-toxins."

Funding for these studies was provided by the National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA) under contract HHSN27220070033C and by the Department of Defense under contract WB81XWH-07-2-0036.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,835.64 +115.72 0.65%
S&P 500 2,096.35 +15.94 0.77%
NASDAQ 5,145.3910 +36.7250 0.72%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs